Table 1 Characteristics of patients

Age at diagnosis

55 [36.50–64.50]

54.40 [41.00–66.00]

55.00 [33.00–63.75]

0.596

Body mass index (BMI) kg/m²

23.85 ± 3.90

23.73 ± 3.09

23.95 ± 4.52

0.427

PHEO/abdominal PGL, n (%)

35 (87.50)/5 (12.50)

14 (77.8)/4 (22.2)

20 (90.9)/2 (9.1)

0.381

Mutated patients, n (%)

12/34 (35.30)

RET 5 (41.7)

SDHB 3 (25)

NF1 2 (16.7)

PHD2 1 (16.7)

VHL 1 (8.3)

4/18 (22.2)

RET 2 (11.1)

SDHB 1 (5.6)

NF1 1 (5.6)

PHD2 0 (0.0)

VHL 0 (0.0)

8/22 (36.4)

RET 3 (13.6)

SDHB 2 (9.1)

NF1 1 (4.5)

PHD2 1 (4.5)

VHL 1 (4.5)

0.853

Surgical approach

Laparoscopic 36 (90)

Laparoscopic 15 (83.3)

Laparoscopic 21 (95.5)

0.310

Laparotomic 4 (10)

Laparotomic 3 (16.7)

Laparotomic 1 (4.5)

Secretory phenotype

Noradrenergic 18 (45.00)

Noradrenergic 8 (44.4)

Noradrenergic 10 (45.5)

 Noradrenergic/adrenergic, n (%)

Adrenergic 22 (55.00)

Adrenergic 10 (55.6)

Adrenergic 12 (54.5)

1.000

Secretory phenotype

 Urinary metanephrine (µg/24 h)

513 [132.25–1435.25]

610.5 [174.75–1960]

418 [119.75–1307.75]

0.652

 Urinary normetanephrine (µg/24 h)

1256.5 [712–4439]

1705.50 [850.75–4990.25]

1073 [568.75–3917]

0.229

Tumor size (mm)

39.20 ± 16.17

41.94 ± 20.67

36.95 ± 11.30

0.367

Preoperative antihypertensive therapy

0.101

 Alpha blockers, n (%)

25 (62.50)

9 (50.0)

17 (77.3)

 Alpha blockers + others, n (%)

15 (37.50)

9 (50.0)

5 (22.7)

Mean doxazosin daily dose (mg)

4.90 ± 2.80

6.06 ± 3.60

3.95 ± 1.58

0.018

Pre-surgical systolic blood pressure (SBP) mmHg

127.15 ± 16.24

131.94 ± 16.73

123.23 ± 15.08

0.048

Pre-surgical dyastolic blood pressure DBP mmHg

76.03 ± 11.16

76.11 ± 11.44

75.95 ± 11.19

0.483

Cardiological comorbidities, n (%)

6 (15.00)

5 (27.8)

1 (4.5)

0.073

Diabetes mellitus, n (%)

1 (2.50)

0 (0.0)

1 (4.5)

1.000

Adequately prepared (AP), n (%)

31 (77.5)

11 (61.1)

20 (90.9)

0.031

ASA Physical Status Classification System, n (%)

I 14 (35)

I 6 (33.3)

I 8 (36.4)

0.844

II 26 (65)

II 12 (66.7)

II 14 (63.6)